Gene therapy injection could ease chronic bladder pain
NCT ID NCT07391306
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a gene therapy called Neovasculgen for people with painful bladder syndrome/interstitial cystitis, a condition causing pelvic pain and frequent urination. The treatment is injected into the bladder wall during a procedure. The goal is to reduce pain and prevent the bladder from shrinking. The trial involves 180 women aged 18-65 and compares the drug to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Neovasculgen (a gene therapy that promotes blood vessel growth)
- What this could lead to
- If it works, this could offer a new treatment option for people with painful bladder syndrome, reducing pain and preventing bladder shrinkage.
- What could go wrong
- This is an early-to-mid stage trial with only 180 participants. The treatment involves injections into the bladder wall, which carries risks like infection or bleeding. It may not work better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Botkin Hospital
RECRUITINGMoscow, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.